SCHEMBL23497864

SCHEMBL23497864

Fc1ccc(-c2cnc(CNc3nc(N4CCOCC4)nc4c(Br)cnn34)[nH]2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK1E P49674 11/20 0.50
▸ CSNK1D P48730 10/20 0.50
▸ MAPT P10636 1/20 0.38
▸ HTR2C P28335 1/20 0.38
▸ CASP1 P29466 4/20 0.37
▸ CASP7 P55210 4/20 0.37
▸ HIF1A Q16665 4/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ CLK4 Q9HAZ1 1/20 0.37
▸ ALDH1A1 P00352 4/20 0.37
▸ CYP1A2 P05177 4/20 0.37
▸ HSD17B10 Q99714 3/20 0.37
▸ TSHR P16473 2/20 0.37
▸ GLA P06280 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ USP2 O75604 2/20 0.37
▸ HPGD P15428 2/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23508302 0.91 CSNK1E (0.45) CSNK1ECSNK1DCASP1CASP7HIF1A
SCHEMBL23508497 0.91 CSNK1D (0.53) CSNK1ECSNK1DCASP1CASP7HIF1A
SCHEMBL30590462 0.91 CSNK1E (0.45) CSNK1ECSNK1DCDK13CDK12ABL1
SCHEMBL23508248 0.90 CSNK1D (0.57) CSNK1ECSNK1DCDK13CDK12PIK3CA
SCHEMBL30590457 0.89 CSNK1E (0.43) CSNK1ECSNK1DABL1BCR
SCHEMBL23508279 0.87 CSNK1E (0.39) CSNK1ECSNK1DMAPTHTR2CCASP1
SCHEMBL23508520 0.86 CSNK1E (0.45) CSNK1ECSNK1DALDH1A1CDK13CDK12
SCHEMBL30013573 0.86 CSNK1E (0.45) CSNK1ECSNK1DALDH1A1CDK13CDK12
SCHEMBL23497510 0.86 CSNK1D (0.45) CSNK1ECSNK1DPIK3CA
SCHEMBL23508328 0.85 CSNK1E (0.48) CSNK1ECSNK1DCDK13CDK12ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117034-A1 PYRAZOLOTRIAZINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-20 — — US disclosed
US-20230117034-A1 PYRAZOLOTRIAZINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-20 — — US disclosed
EP-4073072-A1 PYRAZOLOTRIAZINES Bayer Aktiengesellschaft (DE) 2022-10-19 — — EP disclosed
WO-2021116178-A1 PYRAZOLOTRIAZINES BAYER AKTIENGESELLSCHAFT (DE) 2021-06-17 — — WO disclosed
WO-2021116178-A1 PYRAZOLOTRIAZINES BAYER AKTIENGESELLSCHAFT (DE) 2021-06-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117034-A1 PYRAZOLOTRIAZINES BRCA1, TPX2, CCND2 CSNK1E 1596/4885CSNK1D 963/4885MAPT 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback